ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA – Get Free Report)’s stock price was up 0.3% during trading on Thursday . The company traded as high as $0.2125 and last traded at $0.2107. Approximately 23,766 shares traded hands during mid-day trading, a decline of 59% from the average daily volume of 57,653 shares. The stock had previously closed at $0.21.
ZyVersa Therapeutics Price Performance
The firm has a market capitalization of $1.75 million, a price-to-earnings ratio of -0.16 and a beta of 0.71. The business’s fifty day simple moving average is $0.22 and its 200 day simple moving average is $0.18.
About ZyVersa Therapeutics
ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.
Featured Articles
Receive News & Ratings for ZyVersa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZyVersa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
